MAGEC2 and melanoma: TCR-T therapies have been developed to target a range of melanoma-associated antigens expressed in UM, including PRAME (preferentially expressed antigen in melanoma), MAGE-C2 (melanoma-associated antigen C2), SLC45A2, and MART-1 (melanoma antigen recognized by T cells-1).